CMER are shown. The case of presurgical axitinib showed a 7% and 27% tumor reduction by RECIST and CMER, respectively (A). The case of presurgical everolimus showed a 1.1% reduction by RECIST but 22% tumor progression was observed by CMER (B). The case of presurgical axitinib showed an 11% and 78% tumor reduction by RECIST and CMER, respectively (C). The case of presurgical axitinib showed a 39% and 87% tumor reduction by RECIST and CMER, respectively (D). This patient experienced a pT0 tumor 4.6 months after presurgical axitinib.
Supplementary
Acute kidney injury 1 (3.2%) 3
Deep vein thrombus 1 (3.2%) 2
Liver dysfunction 1 (3.2%) 2
Superficial wound dehiscence 1 (3.2%)
